Galderma Current Deferred Revenue from 2010 to 2026
| GALD Stock | 144.10 4.50 3.03% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 1.3 M | Current Value 840.1 K | Quarterly Volatility 323.1 K |
Check Galderma Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galderma Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 265.5 M, Interest Expense of 418 M or Selling General Administrative of 495.8 M, as well as many indicators such as Price To Sales Ratio of 3.27, Dividend Yield of 0.0 or PTB Ratio of 3.29. Galderma financial statements analysis is a perfect complement when working with Galderma Group Valuation or Volatility modules.
Galderma | Current Deferred Revenue |
The evolution of Current Deferred Revenue for Galderma Group N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Galderma Group compares to historical norms and industry peers.
Latest Galderma Group's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Galderma Group N over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Galderma Group's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galderma Group's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Galderma Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 558,406 | |
| Geometric Mean | 491,943 | |
| Coefficient Of Variation | 57.85 | |
| Mean Deviation | 273,806 | |
| Median | 364,460 | |
| Standard Deviation | 323,054 | |
| Sample Variance | 104.4B | |
| Range | 893.8K | |
| R-Value | 0.76 | |
| Mean Square Error | 46.2B | |
| R-Squared | 0.58 | |
| Significance | 0.0003 | |
| Slope | 48,925 | |
| Total Sum of Squares | 1.7T |
Galderma Current Deferred Revenue History
About Galderma Group Financial Statements
Galderma Group investors use historical fundamental indicators, such as Galderma Group's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Galderma Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 M | 840.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Galderma Stock Analysis
When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.